HONG KONG, May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- American Oriental Bioengineering Inc. (AOBO) , today announced findings that soybean protein peptide may inhibit the growth of some tumor cells in mice.
Research conducted at American Oriental Bioengineering's research facility centered on the application of soybean protein peptide towards inhibiting growth of tumor cells in mice. The growth of liver cancer cells inside the mice was successfully suppressed by soybean protein peptide without apparent side effects.
The research focused on stopping the growth of the metastatic tumor cells because of their ability to mutate more quickly than normal cells, which gives them a greater ability to adapt to their environment, as well as a greater ability to resist therapy. Because the liver is close to or actually connected to several significant organs, and because the liver plays an important role in blood circulation by acting as a filter, metastatic liver cancer occurs in over 75% of all terminal cancer patients.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. For more information visit www.bioaobo.com.
Safe Harbor Statement
Except for the historical statements made herein, the statements made in this release are forward-looking statements. Risk factors that could cause actual results to differ materially from those projected in forward-looking statements include, but are not limited to, general business conditions, managing growth, and political and other business risks. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks and other factors detailed in the Company's reports filed with the Securities and Exchange Commission. American Oriental Bioengineering, Inc. undertakes no duty to update these forward-looking statements.